SCYX · Scynexis Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.60M | $3.75M | $140.14M | $5.09M | $13.16M | $0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $22.28M | $26.41M | $30.93M | $27.26M | $23.77M | $36.52M |
| SG&A | $14.39M | $14.46M | $20.92M | $62.96M | $49.92M | $14.63M |
| Total Operating Expenses | $36.67M | $40.86M | $67.47M | $90.85M | $74.00M | $51.15M |
| D&A | - | $0 | $580.0K | $606.0K | $111.0K | $111.0K |
| Operating Income | ($16.07M) | ($37.12M) | $72.67M | ($85.76M) | ($60.84M) | ($51.15M) |
| Interest Expense | $173.0K | $828.0K | $3.13M | $5.20M | $2.66M | $1.18M |
| Income Tax | $0 | $151.0K | $138.0K | ($4.70M) | ($3.09M) | ($3.15M) |
| Net Income | ($8.61M) | ($21.29M) | $67.04M | ($62.81M) | ($32.87M) | ($55.19M) |
| EPS - Basic | ($1.36) | ($3.52) | $11.20 | ($10.00) | - | - |
| EPS - Diluted | ($1.36) | ($3.52) | $11.12 | ($10.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.26M | $16.05M | $34.05M | $45.81M | $104.48M | $93.04M |
| Accounts Receivable | - | - | $0 | $2.10M | $861.0K | - |
| Inventory | - | - | $0 | $899.0K | $463.0K | - |
| Accounts Payable | $2.23M | $4.57M | $7.15M | $5.94M | $7.85M | $4.64M |
| Current Assets | $40.37M | $72.18M | $102.12M | $79.06M | $109.38M | $98.21M |
| Total Assets | $59.03M | $90.64M | $128.41M | $87.81M | $119.84M | $102.54M |
| Current Liabilities | $5.73M | $24.10M | $16.30M | $17.62M | $13.62M | $26.40M |
| Long-term Debt | - | - | - | - | $28.75M | - |
| Total Liabilities | $9.65M | $35.57M | $55.45M | $84.58M | $78.58M | $79.78M |
| Stockholders' Equity | $49.38M | $55.08M | $72.96M | $3.23M | $41.26M | $22.76M |
| Retained Earnings | ($385.14M) | ($376.54M) | ($355.25M) | ($422.29M) | ($359.48M) | ($326.61M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.28M) | ($24.01M) | $60.16M | ($79.88M) | ($54.56M) | ($49.35M) |
| Investing Cash Flow | $24.31M | $6.15M | ($34.88M) | ($27.39M) | ($1.17M) | $6.47M |
| Financing Cash Flow | ($14.17M) | ($139.0K) | ($36.72M) | $48.60M | $67.12M | $94.00M |
| CapEx | - | - | - | - | $0 | $4.0K |
| Free Cash Flow | - | - | - | - | ($54.56M) | ($49.36M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -78.0% | -990.8% | 51.9% | -1684.5% | -462.2% | - |
| EBITDA margin | - | -990.8% | 52.3% | -1672.6% | -461.3% | - |
| Net margin | -41.8% | -568.3% | 47.8% | -1233.7% | -249.7% | - |
| Free cash flow margin | - | - | - | - | -414.5% | - |
| FCF / Net income | - | - | - | - | 1.66 | 0.89 |
| R&D / Revenue | 108.2% | 704.9% | 22.1% | 535.4% | 180.6% | - |
| SG&A / Revenue | 69.9% | 386.0% | 14.9% | 1236.7% | 379.2% | - |
| Effective tax rate | - | - | 0.2% | - | - | - |
| Return on assets | -14.6% | -23.5% | 52.2% | -71.5% | -27.4% | -53.8% |
| Return on equity | -17.4% | -38.7% | 91.9% | -1942.7% | -79.7% | -242.5% |
| Return on invested capital | - | - | - | - | -68.7% | - |
| Liquidity | ||||||
| Current ratio | 7.04 | 3.00 | 6.26 | 4.49 | 8.03 | 3.72 |
| Quick ratio | 7.04 | 3.00 | 6.26 | 4.44 | 8.00 | 3.72 |
| Cash ratio | 3.71 | 0.67 | 2.09 | 2.60 | 7.67 | 3.52 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.70 | - |
| Debt / Assets | - | - | - | - | 0.24 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -92.9x | -44.8x | 23.2x | -16.5x | -22.9x | -43.3x |
| Equity multiplier | 1.20 | 1.65 | 1.76 | 27.16 | 2.90 | 4.51 |
| Liabilities / Assets | 0.16 | 0.39 | 0.43 | 0.96 | 0.66 | 0.78 |
| Efficiency | ||||||
| Asset turnover | 0.35 | 0.04 | 1.09 | 0.06 | 0.11 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 0d | 151d | 24d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | 1.6x | - | - | - |
| P / B | 0.6x | 1.1x | 11.8x | 101.9x | - | - |
| P / S | 1.5x | 15.7x | 6.2x | 64.7x | - | - |
| EV / EBITDA | - | - | 11.3x | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 449.9% | -97.3% | 2652.7% | -61.3% | - | -100.0% |
| Revenue CAGR (3y) | 59.4% | -34.2% | - | 247.8% | 271.4% | - |
| Revenue CAGR (5y) | - | 98.7% | 252.6% | 81.7% | 119.7% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 56.7% | - | - | -41.0% | -18.9% | -4.6% |
| Net income growth (YoY) | 59.6% | - | - | -91.1% | 40.4% | -2.7% |
| EPS growth (YoY) | 61.4% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -10.5% | -29.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -10.4% | -24.5% | 2156.8% | -92.2% | 81.3% | 76.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$20.60M totalLicense And Service$19.16M · 93.0%
Product$1.44M · 7.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-3.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SCYNEXIS INC against the 5 most active filers in the same SIC group.